Cargando…
Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn
Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optima...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627591/ https://www.ncbi.nlm.nih.gov/pubmed/28786732 http://dx.doi.org/10.1080/19420862.2017.1359455 |
_version_ | 1783268743150829568 |
---|---|
author | Yang, Danlin Giragossian, Craig Castellano, Steven Lasaro, Marcio Xiao, Haiguang Saraf, Himanshu Hess Kenny, Cynthia Rybina, Irina Huang, Zhong-Fu Ahlberg, Jennifer Bigwarfe, Tammy Myzithras, Maria Waltz, Erica Roberts, Simon Kroe-Barrett, Rachel Singh, Sanjaya |
author_facet | Yang, Danlin Giragossian, Craig Castellano, Steven Lasaro, Marcio Xiao, Haiguang Saraf, Himanshu Hess Kenny, Cynthia Rybina, Irina Huang, Zhong-Fu Ahlberg, Jennifer Bigwarfe, Tammy Myzithras, Maria Waltz, Erica Roberts, Simon Kroe-Barrett, Rachel Singh, Sanjaya |
author_sort | Yang, Danlin |
collection | PubMed |
description | Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optimal binding kinetic framework and extent of pH dependence for these antibodies to maximize target clearance from circulation are not well understood. We have identified a series of naturally-occurring high affinity antibodies with pH-dependent target binding properties. By in vivo studies in cynomolgus monkeys, we show that pH-dependent binding to the target alone is not sufficient for effective target removal from circulation, but requires Fc mutations that increase antibody binding to FcRn. Affinity-enhanced pH-dependent FcRn binding that is double-digit nM at pH 7.4 and single-digit nM at pH 6 achieved maximal target reduction when combined with similar target binding affinities in reverse pH directions. Sustained target clearance below the baseline level was achieved 3 weeks after single-dose administration at 1.5 mg/kg. Using the experimentally derived mechanistic model, we demonstrate the essential kinetic interplay between target turnover and antibody pH-dependent binding during the FcRn recycling, and identify the key components for achieving maximal target clearance. These results bridge the demand for improved patient dosing convenience with the “know-how” of therapeutic modality by design. |
format | Online Article Text |
id | pubmed-5627591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-56275912017-10-12 Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn Yang, Danlin Giragossian, Craig Castellano, Steven Lasaro, Marcio Xiao, Haiguang Saraf, Himanshu Hess Kenny, Cynthia Rybina, Irina Huang, Zhong-Fu Ahlberg, Jennifer Bigwarfe, Tammy Myzithras, Maria Waltz, Erica Roberts, Simon Kroe-Barrett, Rachel Singh, Sanjaya MAbs Report Antibodies with pH-dependent binding to both target antigens and neonatal Fc receptor (FcRn) provide an alternative tool to conventional neutralizing antibodies, particularly for therapies where reduction in antigen level is challenging due to high target burden. However, the requirements for optimal binding kinetic framework and extent of pH dependence for these antibodies to maximize target clearance from circulation are not well understood. We have identified a series of naturally-occurring high affinity antibodies with pH-dependent target binding properties. By in vivo studies in cynomolgus monkeys, we show that pH-dependent binding to the target alone is not sufficient for effective target removal from circulation, but requires Fc mutations that increase antibody binding to FcRn. Affinity-enhanced pH-dependent FcRn binding that is double-digit nM at pH 7.4 and single-digit nM at pH 6 achieved maximal target reduction when combined with similar target binding affinities in reverse pH directions. Sustained target clearance below the baseline level was achieved 3 weeks after single-dose administration at 1.5 mg/kg. Using the experimentally derived mechanistic model, we demonstrate the essential kinetic interplay between target turnover and antibody pH-dependent binding during the FcRn recycling, and identify the key components for achieving maximal target clearance. These results bridge the demand for improved patient dosing convenience with the “know-how” of therapeutic modality by design. Taylor & Francis 2017-08-08 /pmc/articles/PMC5627591/ /pubmed/28786732 http://dx.doi.org/10.1080/19420862.2017.1359455 Text en © 2017 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
spellingShingle | Report Yang, Danlin Giragossian, Craig Castellano, Steven Lasaro, Marcio Xiao, Haiguang Saraf, Himanshu Hess Kenny, Cynthia Rybina, Irina Huang, Zhong-Fu Ahlberg, Jennifer Bigwarfe, Tammy Myzithras, Maria Waltz, Erica Roberts, Simon Kroe-Barrett, Rachel Singh, Sanjaya Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title | Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title_full | Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title_fullStr | Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title_full_unstemmed | Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title_short | Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn |
title_sort | maximizing in vivo target clearance by design of ph-dependent target binding antibodies with altered affinity to fcrn |
topic | Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627591/ https://www.ncbi.nlm.nih.gov/pubmed/28786732 http://dx.doi.org/10.1080/19420862.2017.1359455 |
work_keys_str_mv | AT yangdanlin maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT giragossiancraig maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT castellanosteven maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT lasaromarcio maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT xiaohaiguang maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT sarafhimanshu maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT hesskennycynthia maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT rybinairina maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT huangzhongfu maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT ahlbergjennifer maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT bigwarfetammy maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT myzithrasmaria maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT waltzerica maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT robertssimon maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT kroebarrettrachel maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn AT singhsanjaya maximizinginvivotargetclearancebydesignofphdependenttargetbindingantibodieswithalteredaffinitytofcrn |